Waist Circumference Measurements in Schizophrenic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-08-01

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prevalence of metabolic syndrome(MS) among pt's with schizophrenia has been reported to be high, ranging from 24 to 43% in males and 27 to 52% in females. Schizophrenic patients with MS have an increased incidence of DM, coronary heart disease and increased mortality from cardiovascular diseases. Central adiposity is highly correlated with the presence of hypertension, coronary heart disease, type 2 diabetes, and increased mortality risk. Waist circumference(WC) is a better indicator of abdominal obesity and a better predictor of CVD than either BMI or waist-to-hip ratio. However, currently there is no standard location for the measurement of WC.

Objectives: 1. To compare the magnitude of WC measured at 3 sites ( immediately above the iliac crest, midpoint between the lowest rib and the iliac crest , umbilical level) in males and females.

2\. To examine the correlation of WC with Triglyceride, cholesterol, HDL, LDL and glucose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan

NCT01170689

Schizophrenia Obesity

COMPLETED

Prevalence of and Factors Associated With Metabolic Syndrome in Schizophrenia

NCT01587521

Metabolic Syndrome Quality of Life Depression

COMPLETED

The Effectiveness of Lower Extremity Strength Training

NCT07183969

Patients With Chronic Schizophrenia

COMPLETED NA

Feasibility and Preliminary Effect of Baduanjin Program for People Diagnosed With Schizophrenia

NCT04027634

Randomized Controlled Trial

COMPLETED NA

Coronary Artery Disease in Patients Suffering From Schizophrenia

NCT02885792

Schizophrenia Cardiovascular Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Waist Circumference Measurements Schizophrenia Cardiovascular Risk Factor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Patients with schizophrenia or schizoaffective disorder (DSM-IV 295) age 18 till 65 years old.

* Body weight change less than 1 kg in previous one month before index date.

Exclusion Criteria

* • Patients with a previous hyperlipidemia diagnosis or antilipemic prescription during the preceding 30 days.

* Patients received any anti-hypertensives or oral hypoglycemic agents.
* Pregnant or breast-feeding women.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No